SEATTLE, WA, USA /August 7, 2024 /EinPresswire.com/ — Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced 12-month clinical results in the ongoing human trial of its STARgraft arteriovenous (AV) graft (NCT05729620). STARgraft is a new AV graft technology designed to provide kidney failure patients with a safer and more reliable way to access the bloodstream for hemodialysis treatment. Its design is aimed at resisting the most common causes of failure in on-market AV grafts: flow blockage and infection.

Read more.